Mar 5, 2002 16:00
22 yrs ago
2 viewers *
English term
investigational agents
English to Hungarian
Medical
"Other treatment options include standard radiation therapy, chemotherapy, or other methods of brachytherapy or investigational agents to make you feel better, but those do not necessarily cure or lessen the amount or intensity of the disease."
"kutatási hatóanyag" lenne? olyan furcsán hangzik... valami jobb megoldás?
"kutatási hatóanyag" lenne? olyan furcsán hangzik... valami jobb megoldás?
Proposed translations
(Hungarian)
| 4 | fejlesztés alatt álló hatóanyag/gyógyszer |
Attila Piróth
|
Proposed translations
19 mins
Attila Piróth
France
France
Native in Hungarian
France
PhD, ATA-certified En-Hu, sci-tech-IT
Native in: Hungarian 
Works in: English to Hungarian, French to Hungarian, Hungarian to English, and 2 more.
Related KudoZ points
:
2671
Selected
fejlesztés alatt álló hatóanyag/gyógyszer
Az alábbi részből szerintem kitetszik, hogy miről van szó: egy fejlesztés alatt álló hatóanyagról (ágensről), melyet a gyógyszer forgalmazása előtt több betegcsoporton kipróbálnak.
Product Candidate: IDEC-152 (anti-CD23)
IDEC-152 has the potential to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. IDEC's monoclonal antibody binds to the CD23 receptor. By binding to this receptor, IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways.
Clinical Trial Update
In March 2001 at the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in New Orleans. IDEC announced results from a single-dose, placebo-controlled, dose-escalating Phase I trial of its investigational agent IDEC-152, a PRIMATIZEDŽ anti-CD23 monoclonal antibody in patients with allergic asthma.
Product Candidate: IDEC-152 (anti-CD23)
IDEC-152 has the potential to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. IDEC's monoclonal antibody binds to the CD23 receptor. By binding to this receptor, IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways.
Clinical Trial Update
In March 2001 at the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in New Orleans. IDEC announced results from a single-dose, placebo-controlled, dose-escalating Phase I trial of its investigational agent IDEC-152, a PRIMATIZEDŽ anti-CD23 monoclonal antibody in patients with allergic asthma.
4 KudoZ points awarded for this answer.
Comment: "köszi Attila! Nem sejtettem, hogy az orvosi szakszövegekben is járatos vagy :))"
Something went wrong...